TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04485689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical - alone
Description: 5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - alone
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical - ice
Description: 5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - ice
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
Study: NCT03476876

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dermacell
Description: Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
Study: NCT01711359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Administered orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Administered orally every day
Study: NCT03476876

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Integra
Description: Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
Study: NCT01845727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Amphotericin B at 3%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Amphotericin B at 3%
Study: NCT02492360

Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Six tubes of blood will be collected during one blood draw.

Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Six tubes of blood will be collected during one blood draw.

Intervention type: BEHAVIORAL
Intervention: Report of peripheral neuropathy after cisplatin therapy
Description: Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.

Intervention type: BEHAVIORAL
Intervention: Report of peripheral neuropathy after cisplatin therapy
Description: Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
Study: NCT03610620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vivascope 2500 ex-vivo fluorescent confocal microscope
Description: scanned with the Vivascope 2500
Study: NCT01293643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg clindamycin /800 mg ketoconazole vaginal ovule
Description: 1 vaginal ovule for 3 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
Description: 1 applicator (4 g) full of cream intravaginally for 7 to 10 days
Study: NCT03180398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Description: MRI will be acquired before, during and after radiation treatment to evaluate treatment response
Study: NCT01863134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00385723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 (Fish Oil) Supplementation
Description: 1.25 g or 2.496 g daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 (Fish Oil) Supplementation
Description: 1.25 g or 2.496 g daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule daily for 4 months
Study: NCT01555554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo.
Study: NCT02914548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Study: NCT01711359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Administered orally every day
Study: NCT01886092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 1
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 2
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
Study: NCT03420651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow Rate (PEFR)
Description: PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Clinical Judgement
Description: Providers will use physical exam and standard clinical judgement to guide management.
Study: NCT01184625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 12 weeks of physical exercise.
Study: NCT03176992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL®
Description: insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
Study: NCT00483808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ardian Symplicity™ Catheter
Description: Renal denervation using the Symplicity Catheter
Study: NCT04290689

Intervention type: DRUG
Intervention: Botulinum Toxin-A injection
Description: Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.

Intervention type: PROCEDURE
Intervention: Serial casting stretching
Description: Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
Study: NCT01574612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir/hydrocortisone cream
Description: cream applied topically to lesion five times daily for five days
Study: NCT04487054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pro-active palliative care
Description: Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
Study: NCT01782261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: once daily subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: once daily tablet
Study: NCT04061096

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
Study: NCT01739582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Study: NCT02653456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RA-308 Excimer Laser and DABRA Catheter
Description: See information already included in arm description
Study: NCT02621411

Intervention type: DRUG
Intervention: Substance use
Description: Patients are found use of substances by preoperative screen
Study: NCT01540656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)
Description: A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)
Description: A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.
Study: NCT01886092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 3
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham condition
Description: Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
Study: NCT06152367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPCells vaccine
Description: Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
Study: NCT00090844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: 3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
Study: NCT01835236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
Study: NCT00570089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Study: NCT03619369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision
Description: Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision
Description: Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Circumcision
Description: Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
Study: NCT02812550

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonoscopy procedure
Description: endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonoscopy procedure
Description: endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
Study: NCT01675401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-loss treatment
Description: A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: No-weight loss treatment
Description: Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
Study: NCT02495064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Cream
Description: One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
Study: NCT01484834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise were prescribed three times a week with duration of fifteen minutes for three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Company
Description: No intervention was applied for the participants of this group
Study: NCT02256410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
Study: NCT00022165

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: selenium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Study: NCT03076775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal glycemic control
Description: Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
Study: NCT02317029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a pulsed biphasic waveform
Description: Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a pulsed biphasic waveform
Description: Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia during cardioversion
Description: Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
Study: NCT00171223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571
Description: STI571 oral capsules or tablets.